Clinical Trials
-
Getty Images
Obesity drugsPfizer dips on new data for obesity drug acquired in $10B deal
A long-acting shot Pfizer got through a buyout of Metsera appeared “slightly inferior” to Lilly’s market-leading Zepbound in a Phase 2 trial, one analyst said.
By Jonathan Gardner • Feb. 3, 2026 -
Courtesy of Novo Nordisk
Obesity drugsNovo combination obesity shot meets goal in diabetes trial
CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to rival Lilly's Zepbound.
By Jonathan Gardner • Feb. 2, 2026 -
Explore the Trendline➔
Getty Images
TrendlineNeuroscience drug development
Enthusiasm is running higher among drugmakers and investors for neuroscience drug development, buoyed by recent approvals of new Alzheimer’s, ALS and depression medicines.
By BioPharma Dive staff -
Courtesy of Sanofi
Sanofi drug, inherited from Genzyme, goes 1-for-2 in rare disease trials
The drug, which has suffered multiple setbacks over the years, could finally reach the market as a treatment for a form of Gaucher disease.
By Delilah Alvarado • Feb. 2, 2026 -
Alamy
Amgen gives up on its once-prized eczema drug
The decision comes more than a year after disappointing initial Phase 3 results and casts further doubt on a class of autoimmune drugs thought to be challengers to treatments like Dupixent.
By Jonathan Gardner • Jan. 30, 2026 -
Courtesy of Intellia Therapeutics
Gene editingFDA lifts hold on an Intellia CRISPR drug trial
Intellia is instituting new safeguards following the death of a study participant that led regulators to pause two trials in people with transthyretin amyloidosis. One of those tests remains suspended.
By Delilah Alvarado • Jan. 27, 2026 -
Permission granted by Roche
Obesity drugsRoche, trailing in obesity, showcases new data for GLP-1 shot
A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.
By Jonathan Gardner • Jan. 27, 2026 -
Jacob Bell/BioPharma Dive
Sarepta, battling slowing sales, claims Duchenne gene therapy’s impact grows with time
On a Monday conference call, Sarepta CEO Doug Ingram said new long-term data should help “rebalance the discussion” surrounding Elevidys.
By Jonathan Gardner • Jan. 26, 2026 -
Permission granted by Sanofi
Sanofi to seek approval of touted eczema drug despite mixed results
Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects.
By Jonathan Gardner • Jan. 23, 2026 -
Alamy
FDA lays out new path to speed development of multiple myeloma drugs
In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.
By Jonathan Gardner • Jan. 22, 2026 -
Getty Images
Corvus shares nearly triple on positive data for eczema pill
While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.
By Jonathan Gardner • Jan. 21, 2026 -
1nHealth
Sponsored by 1nHealthThe patient retention crisis is happening before enrollment even begins
The biggest patient drop-off happens before patients ever enroll.
By Katie Rodammer • Jan. 20, 2026 -
Permission granted by Almac Clinical Services
Sponsored by Almac Clinical ServicesWhen every day counts: Building CRO partnerships on a foundation of trust, care and precision
Clinical trial delays impact outcomes. Learn why CROs need a supply chain partner they can trust to reduce delays and help patients.
Jan. 20, 2026 -
Getty Images
Tecvayli tops standard drugs in early multiple myeloma, J&J says
The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.
By Jonathan Gardner • Jan. 15, 2026 -
Permission granted by Sanofi
What Sanofi’s multiple sclerosis troubles could mean for the space
Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many opportunities to make an impact.
By Kelly Bilodeau • Jan. 13, 2026 -
Sean Anthony Eddy via Getty Images
Sponsored by PearsonBest practices for COA selection: Building a stronger foundation for clinical trials
In a time when COAs are more nuanced, critical and complex than ever, researchers can turn to best practices to move forward efficiently while maintaining scientific and regulatory rigor.
Jan. 12, 2026 -
Getty Images
GSK, Ionis claim study success for RNA-based hepatitis B drug
The companies didn’t provide details, but said global regulatory filings are now planned for the therapy, an oligonucleotide meant to provide “functional cures” for chronic hepatitis B infections.
By Kristin Jensen • Jan. 7, 2026 -
Getty Images
Alumis soars as TYK2 drug hits mark in psoriasis trials
Shares more than doubled in value after Phase 3 results suggested Alumis’ pill may compare favorably with other emerging oral options for psoriasis, among them drugs from Takeda and Johnson & Johnson.
By Jonathan Gardner • Jan. 6, 2026 -
Getty Images
Zenas shares crash after top drug misses expectations in immune disease study
While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear to match the effectiveness of a recently approved Amgen drug.
By Jonathan Gardner • Jan. 5, 2026 -
Permission granted by LifeLabs
Sponsored by LifeLabsStrategic diagnostic testing partnerships are accelerating clinical research
With the rise of biologics, precision medicine and AI-driven drug discovery, clinical research has entered a new and complex era.
Jan. 5, 2026 -
Kendall Davis/BioPharma Dive
Tracker10 clinical trials to watch in the first half of 2026
After a lengthy downturn, the biotech industry finally gathered momentum in 2025. Key readouts in obesity, infectious disease and many rare conditions could help it continue.
By BioPharma Dive staff • Jan. 5, 2026 -
Alamy
Patient deaths put Merck, Daiichi’s ADC trial on partial hold
The FDA placed the hold after researchers recorded a “higher than anticipated” incidence of deaths in a study testing “I-DXd” in people with small cell lung cancer.
By Delilah Alvarado • Dec. 19, 2025 -
Getty Images
News roundupNovo files for CagriSema approval; Merck and Pfizer’s trial win
Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.
By BioPharma Dive staff • Dec. 19, 2025 -
Courtesy of Galapagos
Galapagos TYK2 drug hits goal in one trial, misses in another
The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin and muscle disorder but missed in a lupus study.
By Jonathan Gardner • Dec. 19, 2025 -
Getty Images
Obesity drugs
Lilly obesity pill, headed for quick FDA review, hits mark in ‘maintenance’ trial
Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could broaden its use in obesity.
By Jonathan Gardner • Dec. 18, 2025 -
Getty Images
Insmed’s ‘win streak’ ends as top drug fails study in chronic nasal condition
The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely followed lung disease medicine.
By Kristin Jensen • Dec. 18, 2025
